OQS
STRO icon

Occudo Quantitative Strategies’s Sutro Biopharma STRO Stock Holding History

Occudo Quantitative Strategies’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,455
Closed -$247K – 1347
2022
Q3 		$247K Sell
4,455
-3,820
-46% -$226K 0.02% 907
2022
Q2 		$431K Buy
+8,275
New +$462K 0.04% 672

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Occudo Quantitative Strategies's STRO Position: Q4 2022 in Review

Occudo Quantitative Strategies sold out of Sutro Biopharma (STRO) in Q4 2022, closing a stake of 4,455 shares — an estimated $247K sold.

Occudo Quantitative Strategies first reported a position in STRO in Q2 2022 and held it in 2 quarters. The position peaked at $431K in Q2 2022. 118 funds tracked by Wall St. Rank hold STRO as of Q4 2022.

  • Occudo Quantitative Strategies reported no remaining Sutro Biopharma position as of Q4 2022 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 4,455 Sutro Biopharma shares in Q4 2022, an estimated $247K.
  • Occudo Quantitative Strategies first reported a position in Sutro Biopharma in Q2 2022 and held it in 2 quarters.
  • Occudo Quantitative Strategies's Sutro Biopharma position peaked at $431K in Q2 2022.
  • 118 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.